Canaccord Genuity began coverage on shares of Heska Corporation (NASDAQ:HSKA) in a report released on Thursday morning, MarketBeat reports. The firm issued a buy rating and a $115.00 price objective on the medical research company’s stock.
Several other equities research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Heska Corporation from a buy rating to a hold rating in a research note on Wednesday, October 4th. BidaskClub lowered shares of Heska Corporation from a buy rating to a hold rating in a research note on Monday, August 14th. Benchmark Co. reaffirmed a buy rating and issued a $120.00 price objective (up previously from $106.00) on shares of Heska Corporation in a research note on Wednesday, August 9th. B. Riley reaffirmed a neutral rating and issued a $96.50 price objective on shares of Heska Corporation in a research note on Thursday, August 3rd. Finally, Aegis lifted their price objective on shares of Heska Corporation from $114.50 to $129.50 and gave the company a buy rating in a research note on Tuesday, August 1st. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Heska Corporation currently has a consensus rating of Hold and an average price target of $106.83.
Shares of Heska Corporation (NASDAQ HSKA) opened at 96.12 on Thursday. The stock’s 50 day moving average price is $94.65 and its 200-day moving average price is $98.32. The firm has a market capitalization of $694.56 million, a P/E ratio of 48.99 and a beta of 0.85. Heska Corporation has a 12-month low of $46.51 and a 12-month high of $115.00.
Heska Corporation (NASDAQ:HSKA) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The business had revenue of $34.30 million during the quarter, compared to analyst estimates of $33.35 million. During the same quarter in the previous year, the business earned $0.35 EPS. Heska Corporation’s quarterly revenue was up 14.3% compared to the same quarter last year. On average, equities analysts expect that Heska Corporation will post $2.04 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/heska-corporation-hska-coverage-initiated-at-canaccord-genuity/1700758.html.
In related news, EVP Nancy Wisnewski sold 825 shares of Heska Corporation stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $102.21, for a total value of $84,323.25. Following the transaction, the executive vice president now owns 38,114 shares in the company, valued at approximately $3,895,631.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO John Mcmahon sold 2,608 shares of Heska Corporation stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total transaction of $263,851.36. Following the completion of the transaction, the chief financial officer now owns 193 shares in the company, valued at approximately $19,525.81. The disclosure for this sale can be found here. Company insiders own 14.70% of the company’s stock.
Large investors have recently bought and sold shares of the company. Victory Capital Management Inc. bought a new position in shares of Heska Corporation during the 1st quarter worth about $101,000. Royal Bank of Canada increased its holdings in shares of Heska Corporation by 96.9% during the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after purchasing an additional 499 shares during the period. BNP Paribas Arbitrage SA increased its holdings in shares of Heska Corporation by 1,306.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,167 shares of the medical research company’s stock worth $123,000 after purchasing an additional 1,084 shares during the period. State of Alaska Department of Revenue bought a new position in shares of Heska Corporation during the 2nd quarter worth about $127,000. Finally, LS Investment Advisors LLC increased its holdings in shares of Heska Corporation by 411.2% during the 2nd quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock worth $130,000 after purchasing an additional 1,028 shares during the period. Institutional investors own 81.36% of the company’s stock.
Heska Corporation Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with our FREE daily email newsletter.